You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
Owning big pharma stocks in recent years has pretty much been a prescription for losing money. Product recalls (Vioxx and Bextra, for example), litigation, patent expirations, generic competition, limp new-drug pipelines and unfavorable publicity have buffeted the sector. Stocks such as Pfizer and Eli Lilly have been mostly falling since early 2004.
But over in Europe, pharmaceutical stocks such as Novartis and Roche have been in ruddy good health. Wendell Perkins, co-manager of JohnsonFamily International Value, recommends Sanofi-Aventis, a French pharma giant formed in a 2004 megamerger. Perkins favors Aventis, the world's third largest drugmaker (after Pfizer and GlaxoSmithKline), for its deep, diverse product portfolio and promising pipeline.
Consider: Aventis boasts billion-dollar blockbuster drugs in categories ranging from anti-coagulants (Lovenox and Plavix) and oncology medicines (Taxotene and Eloxatin) to diabetes (Lantus) and insomnia (Ambien) fighters. The company also sells the leading vaccines for afflictions such as influenza and polio. The sources of Aventis's revenues are well balanced geographically: Europe accounts for 40% of sales, the U.S. for 30%, and the rest of the world the remaining 30%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Aventis's laboratories have been remarkably fertile. They are currently developing 129 products. Perkins thinks Acomplia, an anti-obesity drug expected to receive approval from the Food and Drug Administration in the second half of this year, will be a new blockbuster.
Sanofi-Aventis is still benefiting from large cost savings wrung out of the merged companies. But unlike many U.S. drug companies, sales growth -- 10% in the first quarter of this year -- has remained robust. Trading at $48 a share, Aventis's American depositary receipts (symbol SNY) sell for 14 times the average of analysts' 2006 earnings estimates.
--Andrew Tanzer
-
How Much It Costs to Host a Super Bowl Party in 2026Hosting a Super Bowl party in 2026 could cost you. Here's a breakdown of food, drink and entertainment costs — plus ways to save.
-
3 Reasons to Use a 5-Year CD As You Approach RetirementA five-year CD can help you reach other milestones as you approach retirement.
-
Your Adult Kids Are Doing Fine. Is It Time To Spend Some of Their Inheritance?If your kids are successful, do they need an inheritance? Ask yourself these four questions before passing down another dollar.
-
If You'd Put $1,000 Into AMD Stock 20 Years Ago, Here's What You'd Have TodayAdvanced Micro Devices stock is soaring thanks to AI, but as a buy-and-hold bet, it's been a market laggard.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
